A28 Therapeutics

A28 Therapeutics is a private, clinical-stage biotech company founded in 2021 and based in Cambridge, Massachusetts. The company has developed a targeted oncolytic peptide platform, with its lead candidate AT-101 having completed a Phase 2a study demonstrating a promising safety profile and anti-tumor activity. A28's strategy focuses on developing AT-101 as a potential therapy across multiple cancer types and treatment lines, both as a monotherapy and in combination with existing standards of care. The executive team brings decades of combined life sciences experience to advance this novel therapeutic approach.

Targeted oncolytic peptide conjugate platform. Utilizes a targeting ligand (e.g., LHRH receptor ligand) to deliver a cationic, membrane-disrupting lytic peptide specifically to cancer cells, causing rapid cell death via membrane pore formation.

A28 competes in the crowded oncology space against established modalities (chemotherapy, targeted therapy, immunotherapy) and novel platforms like Antibody-Drug Conjugates (ADCs) and other targeted cytotoxics. Its differentiation lies in its direct, physical membrane-disruption mechanism, which may avoid intracellular resistance pathways. However, it must demonstrate superior efficacy, safety, or convenience to gain market share.